Hypoglycemia in type 2 diabetes: a critical review
Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be i...
Gespeichert in:
Veröffentlicht in: | Biomedicine & pharmacotherapy 2004-12, Vol.58 (10), p.551-559 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 559 |
---|---|
container_issue | 10 |
container_start_page | 551 |
container_title | Biomedicine & pharmacotherapy |
container_volume | 58 |
creator | Murata, Glen H. Duckworth, William C. Hoffman, Richard M. Wendel, Christopher S. Mohler, M. Jane Shah, Jayendra H. |
description | Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability—an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard. |
doi_str_mv | 10.1016/j.biopha.2004.09.001 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67160977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332204001465</els_id><sourcerecordid>67160977</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1df49dead67ad97317ea8b4c4c94bd6ef1b6e6a75ce7e6ec9a0c7295f090ed083</originalsourceid><addsrcrecordid>eNp9kE1LxDAURYMozjj6D0S60V3rSz-SxoUggzrCgBtdhzR51QzttCYdpf_elhbcuXqbcy_3HUIuKUQUKLvdRYVt2k8VxQBpBCICoEdkSUUGIQPgx2QJPEvCJInjBTnzfgcAGUvyU7KgWZYLYPGSxJu-bT6qXmNtVWD3Qde3GMSBsarADv1doALtbGe1qgKH3xZ_zslJqSqPF_Ndkfenx7f1Jty-Pr-sH7ahTgR0ITVlKgwqw7gygieUo8qLVKdapIVhWNKCIVM808iRoRYKNI9FVoIANJAnK3Iz9bau-Tqg72RtvcaqUntsDl4yThkIzgcwnUDtGu8dlrJ1tlaulxTk6Eru5ORKjq4kCDm4GmJXc_-hqNH8hWY5A3A9A8oP75dO7bX1fxwb1Yqx6H7icLAxGHLSa4t7jcY61J00jf1_yS8hf4i_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67160977</pqid></control><display><type>article</type><title>Hypoglycemia in type 2 diabetes: a critical review</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Murata, Glen H. ; Duckworth, William C. ; Hoffman, Richard M. ; Wendel, Christopher S. ; Mohler, M. Jane ; Shah, Jayendra H.</creator><creatorcontrib>Murata, Glen H. ; Duckworth, William C. ; Hoffman, Richard M. ; Wendel, Christopher S. ; Mohler, M. Jane ; Shah, Jayendra H.</creatorcontrib><description>Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability—an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2004.09.001</identifier><identifier>PMID: 15589062</identifier><identifier>CODEN: BIPHEX</identifier><language>eng</language><publisher>Paris: Elsevier SAS</publisher><subject>Biological and medical sciences ; Circadian Rhythm - physiology ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetes mellitus, type II ; Humans ; Hypoglycemia ; Hypoglycemia - blood ; Hypoglycemia - complications ; Hypoglycemia - physiopathology ; Hypoglycemic agents ; Insulin ; Medical sciences ; Pharmacology. Drug treatments ; Risk factors</subject><ispartof>Biomedicine & pharmacotherapy, 2004-12, Vol.58 (10), p.551-559</ispartof><rights>2004 Elsevier SAS</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1df49dead67ad97317ea8b4c4c94bd6ef1b6e6a75ce7e6ec9a0c7295f090ed083</citedby><cites>FETCH-LOGICAL-c390t-1df49dead67ad97317ea8b4c4c94bd6ef1b6e6a75ce7e6ec9a0c7295f090ed083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2004.09.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16332291$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15589062$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murata, Glen H.</creatorcontrib><creatorcontrib>Duckworth, William C.</creatorcontrib><creatorcontrib>Hoffman, Richard M.</creatorcontrib><creatorcontrib>Wendel, Christopher S.</creatorcontrib><creatorcontrib>Mohler, M. Jane</creatorcontrib><creatorcontrib>Shah, Jayendra H.</creatorcontrib><title>Hypoglycemia in type 2 diabetes: a critical review</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability—an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.</description><subject>Biological and medical sciences</subject><subject>Circadian Rhythm - physiology</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetes mellitus, type II</subject><subject>Humans</subject><subject>Hypoglycemia</subject><subject>Hypoglycemia - blood</subject><subject>Hypoglycemia - complications</subject><subject>Hypoglycemia - physiopathology</subject><subject>Hypoglycemic agents</subject><subject>Insulin</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Risk factors</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAURYMozjj6D0S60V3rSz-SxoUggzrCgBtdhzR51QzttCYdpf_elhbcuXqbcy_3HUIuKUQUKLvdRYVt2k8VxQBpBCICoEdkSUUGIQPgx2QJPEvCJInjBTnzfgcAGUvyU7KgWZYLYPGSxJu-bT6qXmNtVWD3Qde3GMSBsarADv1doALtbGe1qgKH3xZ_zslJqSqPF_Ndkfenx7f1Jty-Pr-sH7ahTgR0ITVlKgwqw7gygieUo8qLVKdapIVhWNKCIVM808iRoRYKNI9FVoIANJAnK3Iz9bau-Tqg72RtvcaqUntsDl4yThkIzgcwnUDtGu8dlrJ1tlaulxTk6Eru5ORKjq4kCDm4GmJXc_-hqNH8hWY5A3A9A8oP75dO7bX1fxwb1Yqx6H7icLAxGHLSa4t7jcY61J00jf1_yS8hf4i_</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>Murata, Glen H.</creator><creator>Duckworth, William C.</creator><creator>Hoffman, Richard M.</creator><creator>Wendel, Christopher S.</creator><creator>Mohler, M. Jane</creator><creator>Shah, Jayendra H.</creator><general>Elsevier SAS</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>Hypoglycemia in type 2 diabetes: a critical review</title><author>Murata, Glen H. ; Duckworth, William C. ; Hoffman, Richard M. ; Wendel, Christopher S. ; Mohler, M. Jane ; Shah, Jayendra H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1df49dead67ad97317ea8b4c4c94bd6ef1b6e6a75ce7e6ec9a0c7295f090ed083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Circadian Rhythm - physiology</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetes mellitus, type II</topic><topic>Humans</topic><topic>Hypoglycemia</topic><topic>Hypoglycemia - blood</topic><topic>Hypoglycemia - complications</topic><topic>Hypoglycemia - physiopathology</topic><topic>Hypoglycemic agents</topic><topic>Insulin</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murata, Glen H.</creatorcontrib><creatorcontrib>Duckworth, William C.</creatorcontrib><creatorcontrib>Hoffman, Richard M.</creatorcontrib><creatorcontrib>Wendel, Christopher S.</creatorcontrib><creatorcontrib>Mohler, M. Jane</creatorcontrib><creatorcontrib>Shah, Jayendra H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murata, Glen H.</au><au>Duckworth, William C.</au><au>Hoffman, Richard M.</au><au>Wendel, Christopher S.</au><au>Mohler, M. Jane</au><au>Shah, Jayendra H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypoglycemia in type 2 diabetes: a critical review</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>58</volume><issue>10</issue><spage>551</spage><epage>559</epage><pages>551-559</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><coden>BIPHEX</coden><abstract>Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability—an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.</abstract><cop>Paris</cop><pub>Elsevier SAS</pub><pmid>15589062</pmid><doi>10.1016/j.biopha.2004.09.001</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0753-3322 |
ispartof | Biomedicine & pharmacotherapy, 2004-12, Vol.58 (10), p.551-559 |
issn | 0753-3322 1950-6007 |
language | eng |
recordid | cdi_proquest_miscellaneous_67160977 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Biological and medical sciences Circadian Rhythm - physiology Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - physiopathology Diabetes mellitus, type II Humans Hypoglycemia Hypoglycemia - blood Hypoglycemia - complications Hypoglycemia - physiopathology Hypoglycemic agents Insulin Medical sciences Pharmacology. Drug treatments Risk factors |
title | Hypoglycemia in type 2 diabetes: a critical review |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T20%3A33%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypoglycemia%20in%20type%202%20diabetes:%20a%20critical%20review&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Murata,%20Glen%20H.&rft.date=2004-12-01&rft.volume=58&rft.issue=10&rft.spage=551&rft.epage=559&rft.pages=551-559&rft.issn=0753-3322&rft.eissn=1950-6007&rft.coden=BIPHEX&rft_id=info:doi/10.1016/j.biopha.2004.09.001&rft_dat=%3Cproquest_cross%3E67160977%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67160977&rft_id=info:pmid/15589062&rft_els_id=S0753332204001465&rfr_iscdi=true |